Merck

MRKApproved

Merck & Co., Inc. is a leading research-intensive biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey. With a market valuation of approximately $282 billion, the company has built a legacy of breakthrough medicines and vaccines, including the blockbuster cancer immunotherapy Keytruda and vaccines like Gardasil. Merck operates globally, reaching 92% of the world's countries with its products and serving over 450 million people with medicines and vaccines in 2024.

Market Cap

$282.3B

Employees

60,000-70,000

Focus

AntibodiesBiologicsSmall Molecules

MRK · Stock Price

USD 114.18+32.84 (+40.37%)

Historical price data

AI Company Overview

Technology Platform

Merck operates a comprehensive biopharmaceutical platform encompassing drug discovery, vaccine development, and animal health, enhanced by AI models like KERMT for advancing drug discovery and small molecule lead optimization.

Pipeline Snapshot

1000

1000 drugs in pipeline, 695 in Phase 3

Drug	Indication	Stage
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) ...	Complicated Intra-Abdominal Infections	Phase 3
FOLFIRI+cetuximab	Colorectal Cancer Metastatic	Phase 3
aprepitant + Comparator: placebo (unspecified)	Major Depressive Disorder	Phase 3
Tenofovir + lamivudine + raltegravir + Tenofovir + lamivudine + efavirenz	HIV-1 Infection	Phase 3
Lonafarnib (SARASAR)	Carcinoma, Non-small-cell Lung	Phase 3

FDA Approved Drugs

KEYTRUDA QLEXBLASep 19, 2025

ENFLONSIABLAJun 9, 2025

WINREVAIRBLAMar 26, 2024

Opportunities

Merck has significant growth opportunities through its robust oncology pipeline, expanding vaccine portfolio, and increasing global access to healthcare in emerging markets.

The company's AI-driven drug discovery platform and strategic partnerships position it well for continued innovation and market expansion.

Risk Factors

Key risks include patent expiration for major products like Keytruda, intense competitive pressure from biosimilars, regulatory challenges in drug approval processes, and global healthcare cost containment pressures.

Clinical trial failures and manufacturing disruptions also pose ongoing operational risks.

Competitive Landscape

Merck competes with major pharmaceutical companies like Pfizer, Johnson & Johnson, Roche, and Novartis in the global biopharmaceutical market. The company differentiates itself through its strong oncology franchise, established vaccine platform, and commitment to research-intensive drug development with strategic partnerships enhancing its competitive position.

Publications

Patents

Pipeline

1000

FDA Approvals